What Actemra treats.
- Rheumatoid arthritis (moderate to severe)
- Giant cell arteritis
- Systemic juvenile idiopathic arthritis
- Polyarticular juvenile idiopathic arthritis
- Cytokine release syndrome
The mechanism.
Actemra (tocilizumab) blocks interleukin-6 (IL-6), a cytokine that promotes inflammation. By inhibiting IL-6 signaling, Actemra reduces joint inflammation, slows joint damage, and improves function for patients with inflammatory arthritis.
Your Actemra infusion experience.
Actemra infusions take about 1 hour and are given every 4 weeks. Pre-medications are typically not required. We monitor vitals before and after each session. Most patients tolerate Actemra well, though it may slightly increase infection risk during treatment.
Insurance & out-of-pocket cost.
Actemra is covered by most commercial insurance and Medicare Part B when prescribed by your physician for an FDA-approved indication. We verify your benefits before your first infusion and handle prior authorization on your behalf. Most commercially insured patients pay only their standard specialty copay — typically $20–$100 per visit. Manufacturer copay assistance programs may further reduce your cost.